drugset / Trial / NCT00264134
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer. Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |